Your session is about to expire
← Back to Search
Monoclonal Antibodies
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
Phase 1
Waitlist Available
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Summary
This trial aims to test if AMG 133 is safe and can be tolerated by people with obesity.
Eligible Conditions
- Obesity
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Trial Design
5Treatment groups
Experimental Treatment
Placebo Group
Group I: Part C: maridebart cafraglutideExperimental Treatment1 Intervention
Up to 2 open-label, multiple ascending dose cohorts (cohorts 12 to 13) treated with doses previously studied in Part A and Part B.
Group II: Part B: maridebart cafraglutideExperimental Treatment1 Intervention
Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
Group III: Part A: maridebart cafraglutideExperimental Treatment1 Intervention
Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
Group IV: Part A: PlaceboPlacebo Group1 Intervention
Up to 7 single ascending dose cohorts (cohorts 1 to 6 and cohort 11).
Group V: Part B: PlaceboPlacebo Group1 Intervention
Up to 4 multiple ascending dose cohorts (cohorts 7 to 10).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
maridebart cafraglutide
2020
Completed Phase 1
~150
Find a Location
Who is running the clinical trial?
AmgenLead Sponsor
1,466 Previous Clinical Trials
1,401,386 Total Patients Enrolled
10 Trials studying Obesity
1,051 Patients Enrolled for Obesity
MDStudy DirectorAmgen
1,003 Previous Clinical Trials
945,130 Total Patients Enrolled
6 Trials studying Obesity
867 Patients Enrolled for Obesity